CN114652806B - Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof - Google Patents
Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof Download PDFInfo
- Publication number
- CN114652806B CN114652806B CN202210521735.3A CN202210521735A CN114652806B CN 114652806 B CN114652806 B CN 114652806B CN 202210521735 A CN202210521735 A CN 202210521735A CN 114652806 B CN114652806 B CN 114652806B
- Authority
- CN
- China
- Prior art keywords
- extract
- medicine composition
- chloasma
- dai medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a Dai medicine composition for treating chloasma, and a preparation method and application thereof, and belongs to the technical field of medicines. The Dai medicine composition is prepared from the following raw materials in parts by weight: 1-2 parts of turmeric extract, 3-5 parts of mukul extract and 3-5 parts of docynia extract. The Dai medicine composition is prepared by compounding turmeric, fruit of Mumilk and docynia, and the raw materials are well-matched and supplement each other. The Dai medicine composition can effectively inhibit tyrosinase from oxidizing L-tyrosine to generate melanin, can effectively prevent, improve or treat pigmentation dermatosis such as chloasma, especially for postpartum chloasma, has better effect than that of single Dai medicine, and plays a synergistic effect. The Dai medicine composition provided by the invention is used for preparing medicines or cosmetics for preventing, improving and even treating chloasma, and has a good application prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and in particular relates to a Dai medicine composition for treating chloasma, and a preparation method and application thereof.
Background
Chloasma is a common pigmentation type skin disease and is characterized by well-defined, pale brown to dark brown patches scattered on the cheek, forehead, periocular, nose and other sites. The disease is a chronic recurrent disease, is well developed for women in childbearing age, and is one of the main dangerous reasons for abnormal hormone levels such as sex hormone, progestogen, thyroid hormone and the like caused by pregnancy, and the repeated chloasma can affect the appearance of puerperal women and bring a lot of psychological trouble to puerperal women due to poor curative effect of the existing treatment method. The Dai medicine 'four towers theory' considers that women suffer from stagnation of the wind towers due to blood loss and damage of the water towers in the delivery process, and the labor and the escape degree are disturbed due to physical consumption, the water towers cannot restrict the wind towers and the fire towers, the blood circulation is unsmooth, the wind dryness and the blood stasis are further caused, and the four towers are unbalanced in function. The obstruction of blood and water stasis causes the deficiency of qi and blood, which causes the malnutrition of skin and the unsmooth face and the occurrence of chloasma (nano-millihair). The unsmooth operation of the water tower and the stagnation of water and blood can even further cause the patients with postpartum chloasma to have symptoms of hypochondriac distention, chest distress, dysphoria, irritability, poor appetite and other uncomfortable symptoms. Therefore, dai medicine treats postpartum chloasma and focuses on treating both principal and secondary aspects of disease, and through regulating and supplementing water and blood, activating blood and removing spots, enhancing skin immunity, the four-tower function of balancing skin of puerpera is helped, and finally physical and mental health is recovered.
Dai medicine "milli-life" is a common medicine for treating postpartum chloasma by Dai medicine, and the basic source plant is Curcuma longa of Curcuma genus of Zingiberaceae. Dai medicine considers that the Dai medicine has bitter and slightly spicy taste, smell and warm nature, and is added into wind, soil and water towers, and has the effects of clearing away heat and toxic materials, killing parasites and relieving itching, promoting blood circulation and removing blood stasis, and ventilating and relieving pain. Curcumin and its derivatives are the main active ingredients of turmeric and are widely used in cosmetics as antioxidants. Pharmacological studies show that curcumin and derivatives thereof have obvious inhibition activity on tyrosinase and have the effects of whitening and lightening spots, but the bioavailability of the components is not high, and the actual application of the components is affected. If a pharmaceutical composition with excellent effect of treating chloasma can be researched, the trouble of vast chloasma patients can be solved undoubtedly, and the pharmaceutical composition has good application prospect.
The wood milk fruit and docynia delavayi fruit are edible and have rich nutritional values. Also, the wood milk fruit and docynia are important medicinal materials in Dai medicine. Dai medicine considers that the fruits of the wood milk are sour and cool in nature, and enter wind, water and fire towers, and has the effects of dispelling wind, relieving itching and clearing heat and detoxicating; the fruit is sour and cool in nature, enters water and soil tower, and has the effects of clearing heat and detoxicating, astringing and treating sore, and relieving swelling and pain. The effects of the wood milk fruit and docynia for treating chloasma are poor, and the composition of the turmeric, the wood milk fruit and docynia for treating chloasma is not seen at present.
Disclosure of Invention
The invention aims to provide a Dai medicine composition for treating chloasma, and a preparation method and application thereof.
The invention provides a Dai medicine composition which is prepared from the following raw materials in parts by weight: 1-2 parts of turmeric extract, 3-5 parts of mukul extract and 3-5 parts of docynia extract.
Further, the Dai medicine composition is prepared from the following raw materials in parts by weight: 2 parts of turmeric extract, 4 parts of mukul extract and 4 parts of docynia extract.
Further, the preparation method of the turmeric extract comprises the following steps:
pulverizing Curcuma rhizome root, decocting with 5-8 times of water for 4-6 hr, concentrating the extractive solution into extract, loading onto macroporous resin column, eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure to solution density of 1.10-1.15, and lyophilizing.
Further, the mukul extract is a mukul extract;
preferably, the preparation method of the Mumilk fruit extract comprises the following steps:
pulverizing the fruit of Muzhi, extracting with ultrasonic wave for 1-3 times, adding 5-10 times of 70-80% ethanol, mixing filtrates, concentrating under reduced pressure, and lyophilizing to obtain the final product;
more preferably, the ultrasonic extraction power is 150-200W; and/or the ultrasonic extraction temperature is 50-60 ℃; and/or the ultrasonic extraction time is 60-90 min.
Further, the docynia extract is docynia fruit extract;
preferably, the preparation method of the docynia extract comprises the following steps:
crushing docynia delavayi fruits, extracting for 1-3 times by adopting ultrasonic waves, adding ethanol with the concentration of 70-80% by weight which is 5-10 times of the weight of each ultrasonic wave extraction, combining the filtrates, concentrating under reduced pressure, and freeze-drying to obtain the medicinal composition;
more preferably, the ultrasonic extraction power is 150-200W; and/or the ultrasonic extraction temperature is 50-60 ℃; and/or the ultrasonic extraction time is 60-90 min.
The invention also provides a method for preparing the Dai medicine composition, which comprises the following steps:
mixing Curcuma rhizome extract, semen Caesalpiniae Radicis extract, docynia extract uniformly.
The invention also provides application of the Dai medicine composition in preparing medicines for preventing, improving or treating pigmentation dermatosis or medicines for inhibiting tyrosinase from oxidizing L-tyrosine to generate melanin;
preferably, the pigmentation skin disease is chloasma;
more preferably, the chloasma is postpartum chloasma.
The invention also provides application of the Dai medicine composition in preparing cosmetics for fading and removing spots; preferably, the spot is chloasma; more preferably, the chloasma is postpartum chloasma.
The invention also provides a medicine which is a medicine preparation prepared by taking the Dai medicine composition as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients;
preferably, the pharmaceutical formulation is an external formulation;
more preferably, the external preparation is a powder, a paste, a patch.
The invention also provides a cosmetic which is prepared by taking the Dai medicine composition as an active ingredient and adding auxiliary materials or auxiliary ingredients acceptable in cosmetics;
preferably, the cosmetic is a facial mask, essence, lotion, cream.
In the invention, the fruit of the MuNAIGUO refers to the fruit of MuNAIGUO Baccaurea ramiflora of MuNAIGUO genus of Phyllanthaceae; the Docynia delavayi fruit refers to the fruit of the plant Docynia delavayi of the genus Docynia of the family rosaceae , yunnan .
The Dai medicine 'four towers theory' considers that women suffer from stagnation of the wind towers due to blood loss and damage of the water towers in the delivery process, and the labor and the escape degree are disturbed due to physical consumption, the water towers cannot restrict the wind towers and the fire towers, the blood circulation is unsmooth, the wind dryness and the blood stasis are further caused, and the four towers are unbalanced in function. The obstruction of blood and water stasis causes the deficiency of qi and blood, which causes the malnutrition of skin and the unsmooth face and the occurrence of chloasma (nano-millihair). The unsmooth operation of the water tower and the stagnation of water and blood can even further cause the patients with postpartum chloasma to have symptoms of hypochondriac distention, chest distress, dysphoria, irritability, poor appetite and other uncomfortable symptoms. Dai medicine of turmeric is named as "milli-Ming", which is the main medicine of the recipe, has the effects of clearing away heat and toxic material, promoting blood circulation to arrest pain, promoting qi circulation and removing blood stasis, and is bitter and slightly spicy, and is used for treating flatly-hot nature, entering soil, water and wind tower. Dai medicine of the fruit of the wooden milk is named as "pot and hemp fly", and the fruit is sour and cool in taste and enters wind, water and fire tower, and has the effects of dispelling wind, relieving itching and clearing heat and detoxicating. Dai medicine named as Ma-Guo-Mai, which is sour in flavor and cool in nature, is added into water and soil, and has the effects of clearing away heat and toxic materials, astringing to treat sore, and relieving swelling and pain. The Mumilk fruit and docynia delavayi fruit are auxiliary drugs of the method, and assist the main drugs in enhancing the functions of the water tower, promoting the operation of the wind tower and consolidating the curative effect of the soil tower. The three medicines are combined together, so that the Chinese medicinal composition has the effects of regulating and supplementing water and blood, activating blood and removing spots, can help puerpera balance the four-tower function of skin, and finally recovers physical and mental health.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a Dai medicine composition for treating chloasma, which is prepared by compounding turmeric, fruit of Mumilk and docynia, and the raw materials are well-matched and supplement each other. The Dai medicine composition can effectively inhibit tyrosinase from oxidizing L-tyrosine to generate melanin, can effectively prevent, improve or treat pigmentation dermatosis such as chloasma, especially for postpartum chloasma, has better effect than that of single Dai medicine, and plays a synergistic effect. The Dai medicine composition provided by the invention is used for preparing medicines or cosmetics for preventing, improving and even treating chloasma, and has a good application prospect.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Detailed Description
The materials and equipment used in the embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
EXAMPLE 1 preparation of Dai medicine composition of the invention
1. The formula of the raw materials comprises: turmeric extract 2g, mukul extract 4g, docynia extract 4g.
2. Preparation method
(1) Preparation of Dai medicine extract
Pulverizing dried fruit of Armillaria mellea, adding 80% edible ethanol 5 times the weight of the pulverized fruit, and soaking for 24 hr. Ultrasonic extracting at 50deg.C under 150W for 90min, and filtering to obtain filtrate. The ultrasonic extraction was repeated 3 times, the filtrates were combined and concentrated under reduced pressure at 50 ℃. Freeze-drying the concentrated solution to obtain the extract of the fruit of the Mumilk fruit.
(2) Preparation of Dai medicine Ma-fruit Mai ( docynia) extract
Dried docynia delavayi fruit is smashed, added with 80% edible ethanol with the weight of 5 times of that of the dried docynia delavayi fruit, and soaked for 24 hours. Ultrasonic extracting at 50deg.C under 150W for 90min, and filtering to obtain filtrate. Repeating ultrasonic extraction for 3 times, mixing filtrates, concentrating under reduced pressure at 50deg.C, and lyophilizing to obtain docynia delavayi fruit extract.
(3) Preparation of turmeric extract
Pulverizing Curcuma rhizome root, decocting with 5-8 times of water for 4-6 hr, concentrating the extractive solution into extract, loading onto macroporous resin column (LX-T28 macroporous resin, siAnlan Xiao technology New Material Co., ltd.), eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure at 50deg.C to solution density of 1.10-1.15, and lyophilizing to obtain Curcuma rhizome extract.
(4) Preparation of Dai medicine composition of the invention
Turmeric extract, mukul extract and docynia extract were combined in a ratio of 2:4:4, uniformly mixing the components in a weight ratio to obtain the Dai medicine composition.
EXAMPLE 2 preparation of Dai medicine composition of the invention
1. The formula of the raw materials comprises: 1g of turmeric extract, 5g of mukul extract and 5g of docynia extract.
2. Preparation method
(1) Preparation of Dai medicine extract
The preparation method of the fruit extract of the Mumilk fruit is the same as in example 1.
(2) Preparation of Dai medicine Ma-fruit Mai ( docynia) extract
Docynia delavayi fruit extract was prepared in the same manner as in example 1.
(3) Preparation of turmeric extract
Turmeric extract was prepared in the same manner as in example 1.
(4) Preparation of Dai medicine composition of the invention
Turmeric extract, mukul extract and docynia extract were mixed at a ratio of 1:5:5, uniformly mixing the components in a weight ratio to obtain the Dai medicine composition.
EXAMPLE 3 preparation of Dai medicine composition of the invention
1. The formula of the raw materials comprises: turmeric extract 2g, mukul extract 3g, docynia extract 3g.
2. Preparation method
(1) Preparation of Dai medicine extract
The preparation method of the fruit extract of the Mumilk fruit is the same as in example 1.
(2) Preparation of Dai medicine Ma-fruit Mai ( docynia) extract
Docynia delavayi fruit extract was prepared in the same manner as in example 1.
(3) Preparation of turmeric extract
Turmeric extract was prepared in the same manner as in example 1.
(4) Preparation of Dai medicine composition of the invention
Turmeric extract, mukul extract and docynia extract were combined in a ratio of 2:3:3, and uniformly mixing the components according to the weight ratio to obtain the Dai medicine composition.
Example 4 preparation of mask
(1) 10g of 1 or 2 of water-soluble jojoba oil, jojoba gum and biological polysaccharide gum are dissolved by 10g of deionized water;
(2) 10g of 2 or 3 of trehalose, sodium hyaluronate, sodium pyrrolidone carboxylate (NL-50), betaine, and hydroxyethyl urea are dissolved with 10g of deionized water;
(3) 10g of 2 or 3 of glycerol, PEG-26 glycerol ether (Liponic EG-1), 1, 3-butanediol, 1, 2-pentanediol, and propylene glycol were dissolved with 10g of deionized water;
(4) Fully mixing the solutions in the steps (1) - (3);
(5) Adding 10g of the Dai medicine composition prepared in the example 1 into the solution obtained in the step (4), and fully and uniformly mixing;
(6) Adding 2g of one or 2 of ethyl glycerol, 1, 2-octanediol and phenoxyethanol into the product of the step (5), fully mixing, adding 28g of deionized water, mixing, filtering and sterilizing to obtain mask base solution;
(7) And filling a piece of mask paper into each aluminum foil bag, adding 10-20g of mask base solution, and sealing.
Example 5 preparation of other skin Care products
The Dai medicine composition in any one of the embodiments 1 to 3 is adopted as an active ingredient, and conventional auxiliary materials or auxiliary ingredients in the field of cosmetics are added, so that other skin care products such as essence, emulsion, face cream and the like can be prepared according to a conventional method.
Example 6 preparation of a medicament for treating chloasma
The Dai medicine composition of any one of the embodiments 1 to 3 is adopted as an active ingredient, and pharmaceutically conventional auxiliary materials or auxiliary ingredients are added, so that various external preparations for treating chloasma, such as application agents, ointment and the like, can be prepared according to a conventional method.
The beneficial effects of the present invention are demonstrated by specific test examples below.
Test example 1 Dai medicine composition of the present invention inhibiting Activity against tyrosinase
L-tyrosine is used as a substrate, and the ability of Dai medicine extract and composition to inhibit tyrosinase from oxidizing L-tyrosine to generate melanin is respectively measured.
1. Experimental materials
Positive control drug: arbutin (Chengdu Angstrom biosciences Co., ltd.)
A substrate: 2mM L-tyrosine (Chengdu Angstrom Biotechnology Co., ltd.)
Enzyme: tyrosinase, enzyme activity 100U/mL (Chengdu Angstrom Biotechnology Co., ltd.)
Buffer solution: 50mM phosphate buffer (Beijing Solarbio)
2. Experimental method
Preparation of test sample solution: taking dimethyl sulfoxide as a solvent, and adding the positive control medicament in the step (1); (2) turmeric extract prepared according to the method of example 1; (3) the Mumeria nivea extract prepared according to the method of example 1; (4) docynia extract prepared according to the method of example 1; (5) Dai medicine composition 1 (turmeric extract: mukul extract: docynia extract weight ratio = 2:4:4); (6) Dai medicine composition 2 (turmeric extract: mukul extract: docynia extract weight ratio = 1:5:5); (7) Dai medicine composition 3 (turmeric extract: mumilk fruit extract: docynia extract weight ratio=2:3:3) was diluted to 800 μg/mL, 400 μg/mL, 200 μg/mL, 100 μg/mL, 50 μg/mL, 25 μg/mL, respectively.
Each group of reaction solutions was added to 96-well plates, and 3 wells were added to each group of reaction solution, wherein the blank group (100. Mu.L PBS), the blank control group (90. Mu.L PBS and 10. Mu.L tyrosinase), the positive control group (20. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 1 (20. Mu.L turmeric extract solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 2 (20. Mu.L turmeric extract solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 3 (20. Mu.L turmeric extract solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 4 (20. Mu.L Dai medicine composition 1 solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 5 (20. Mu.L Dai medicine composition 2 solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 6 (20. Mu.L Dai medicine composition 3 solution, 70. Mu.L and 10. Mu.L tyrosinase), the reaction group 1 (20. Mu.L turmeric extract solution, 70. Mu.L PBS and 10. Mu.L tyrosinase), the reaction group 3 (20. Mu.L turmeric extract solution), the reaction group (20. Mu.L turmeric extract solution, 70. Mu.L PBS and 80. Mu.L tyrosinase), the reaction group 2 (20. Mu.L PBS and the reaction group 2. Mu.L)Liquid and 80. Mu.L PBS), reaction control group 3 (20. Mu.L doc extract solution and 80. Mu.L PBS), reaction control group 4 (20. Mu.L Dai drug composition 1 solution and 80. Mu.L PBS), reaction control group 5 (20. Mu.L Dai drug composition 2 solution and 80. Mu.L PBS), reaction control group 6 (20. Mu.L Dai drug composition 3 solution and 80. Mu.L PBS). After the reaction solution was added thereto, the reaction was incubated at 37℃for 5 minutes, and then 2mM L-tyrosine 100. Mu.L was added thereto, followed by further incubation at 37℃for 10 minutes. Measuring absorbance value of the reaction product at 490nm by using an enzyme-linked immunosorbent assay instrument, wherein the inhibition rate of tyrosinase is = [1- (A) Reaction set -A Reaction control )/(A Blank group -A Blank control )]X 100% (the reaction group was zeroed with the reaction control group containing the same kind and concentration of the test solution, the blank group was zeroed with the blank group), and IC was calculated by SPSS 18.0 software 50 Values. The above experiment was repeated 3 times.
2. Experimental results
The experimental results in table 1 show that turmeric extract has better inhibition activity on tyrosinase, and the wood milk fruit extract and docynia extract have weak inhibition effect on tyrosinase. Compared with a single Dai medicine extract, the Dai medicine composition has obviously improved tyrosinase inhibition activity, namely under the condition of using fewer turmeric extracts, the tyrosinase inhibition activity is improved, which shows that the three extracts of turmeric extract, muzhui extract and Don extract can play a synergistic effect on tyrosinase inhibition. Of these, dai medicine composition 1 (turmeric extract: muzhi fruit extract: docynia extract weight ratio=2:4:4) has the best inhibitory activity on tyrosinase.
TABLE 1 inhibition activity of tyrosinase by turmeric, mumilk fruit, extract and Dai medicine composition (n=3)
The results show that the Dai medicine composition can effectively inhibit tyrosinase from oxidizing L-tyrosine to generate melanin, and further show that the Dai medicine composition can effectively prevent, improve or treat pigmentation dermatosis such as chloasma, and particularly has the effects of effectively preventing, improving and even treating postpartum chloasma.
In conclusion, the invention provides a Dai medicine composition for treating chloasma, which is prepared by compounding turmeric, mumilk fruit and docynia, and the raw materials are well-matched and supplement each other. The Dai medicine composition can effectively inhibit tyrosinase from oxidizing L-tyrosine to generate melanin, can effectively prevent, improve or treat pigmentation dermatosis such as chloasma, especially for postpartum chloasma, has better effect than that of single Dai medicine, and plays a synergistic effect. The Dai medicine composition provided by the invention is used for preparing medicines or cosmetics for preventing, improving and even treating chloasma, and has a good application prospect.
Claims (15)
1. Dai medicine composition for preventing, improving or treating chloasma is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 1-2 parts of turmeric extract, 3-5 parts of mukul extract and 3-5 parts of docynia extract;
the preparation method of the turmeric extract comprises the following steps: pulverizing Curcuma rhizome root, decocting with 5-8 times of water for 4-6 hr, concentrating the extractive solution into extract, loading onto macroporous resin column, eluting with 8-10 column volume of 75% methanol, collecting eluate, concentrating under reduced pressure to solution density of 1.10-1.15, loading onto macroporous resin column, eluting with 5-6 column volume of 60% methanol, collecting eluate, concentrating under reduced pressure to solution density of 1.10-1.15, and lyophilizing to obtain the final product;
the preparation method of the Mumilk fruit extract comprises the following steps: pulverizing the fruit of Muzhi, extracting with ultrasonic wave for 1-3 times, adding 5-10 times of 70-80% ethanol, mixing filtrates, concentrating under reduced pressure, and lyophilizing to obtain the final product;
the preparation method of the docynia extract comprises the following steps: crushing docynia delavayi fruits, extracting for 1-3 times by adopting ultrasonic waves, adding 5-10 times of 70-80% ethanol by weight each time of ultrasonic wave extraction, combining filtrates, concentrating under reduced pressure, and freeze-drying to obtain the medicinal composition.
2. The Dai medicine composition according to claim 1, wherein: the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 2 parts of turmeric extract, 4 parts of mukul extract and 4 parts of docynia extract.
3. The Dai medicine composition according to claim 1, wherein: in the preparation method of the wood milk fruit extract, the ultrasonic extraction power is 150-200W; the ultrasonic extraction temperature is 50-60 ℃; the ultrasonic extraction time is 60-90 min;
in the docynia extract preparation method, the ultrasonic extraction power is 150-200W; the ultrasonic extraction temperature is 50-60 ℃; the ultrasonic extraction time is 60-90 min.
4. A method for preparing the Dai medicine composition according to any one of claims 1 to 3, characterized in that: it comprises the following steps:
mixing Curcuma rhizome extract, semen Caesalpiniae Radicis extract, docynia extract uniformly.
5. Use of the Dai medicine composition according to any one of claims 1 to 3 for preparing a medicine for preventing, improving or treating pigmentation dermatosis or a medicine for inhibiting tyrosinase from oxidizing L-tyrosine to melanin.
6. Use according to claim 5, characterized in that: the pigmentation dermatosis is chloasma.
7. Use according to claim 6, characterized in that: the chloasma is postpartum chloasma.
8. Use of the Dai medicine composition according to any one of claims 1 to 3 for preparing cosmetics for spot-lightening and spot-removing.
9. Use according to claim 8, characterized in that: the spots are chloasma.
10. Use according to claim 9, characterized in that: the chloasma is postpartum chloasma.
11. A medicament for preventing, ameliorating or treating a pigmentation dermatological disorder, or inhibiting the oxidation of L-tyrosine by tyrosinase to melanin, characterized in that: the Dai medicine composition is a pharmaceutical preparation prepared by taking the Dai medicine composition as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
12. A medicament as claimed in claim 11, wherein: the pharmaceutical preparation is an external preparation.
13. A medicament as claimed in claim 12, wherein: the external preparation is powder, paste and patch.
14. A cosmetic for reducing and eliminating spots is characterized in that: the Dai medicine composition of any one of claims 1-3 is used as an active ingredient, and is added with cosmetically acceptable auxiliary materials or auxiliary ingredients to prepare cosmetics.
15. The cosmetic product according to claim 14, characterized in that: the cosmetic is facial mask, essence, lotion, and cream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210521735.3A CN114652806B (en) | 2022-05-13 | 2022-05-13 | Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210521735.3A CN114652806B (en) | 2022-05-13 | 2022-05-13 | Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114652806A CN114652806A (en) | 2022-06-24 |
| CN114652806B true CN114652806B (en) | 2023-07-07 |
Family
ID=82037562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210521735.3A Active CN114652806B (en) | 2022-05-13 | 2022-05-13 | Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114652806B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193675A (en) * | 2015-10-30 | 2015-12-30 | 中国科学院昆明植物研究所 | Docynia delavayi(Franch.)Schneid. extract as well as preparation method and application of (Docynia delavayi(Franch.)Schneid. in preparation of cosmetics |
-
2022
- 2022-05-13 CN CN202210521735.3A patent/CN114652806B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193675A (en) * | 2015-10-30 | 2015-12-30 | 中国科学院昆明植物研究所 | Docynia delavayi(Franch.)Schneid. extract as well as preparation method and application of (Docynia delavayi(Franch.)Schneid. in preparation of cosmetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114652806A (en) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10098372B2 (en) | Whitening composition and the use thereof | |
| KR101483343B1 (en) | A composition for treating skin diseases comprising complex extract and a cosmetic and skin externals using the same | |
| KR100893106B1 (en) | Composition for promoting hair growth | |
| CN103893345B (en) | Composition containing a natural extract | |
| CN106473987A (en) | The anti-ageing compositionss of whitening and cosmetics | |
| CN106137823A (en) | A kind of whitening spot-eliminating composition and application thereof | |
| CN105125466A (en) | Freckle removing night cream and preparing method thereof | |
| KR101752232B1 (en) | Manufacturing Method of Composition for Hair growth promotion and Hair loss prevention | |
| CN113318214A (en) | External composition for blackening and strengthening hair and preparation method thereof | |
| CN103041042B (en) | Tibetan medicine composition and application of composition in anti-off hair products | |
| CN114983914A (en) | Preparation method of whitening skin care product | |
| CN114432225A (en) | Sunscreen skin care product and preparation method thereof | |
| CN111870573B (en) | Whitening and freckle removing cream and preparation method thereof | |
| KR100717420B1 (en) | A healing composition able to treat allergy and athlete's foot | |
| CN114652806B (en) | Dai medicine composition for preventing, improving or treating chloasma and preparation method and application thereof | |
| KR20090020234A (en) | Cosmetic composition containing herb medicine extracts and powders | |
| CN108261388A (en) | A kind of convergence facial mask and preparation method thereof | |
| KR20100026855A (en) | Skin external application composition for preventing or treating inflammatory skin disease | |
| CN112494408A (en) | Whitening and inflammation diminishing mask liquid and preparation method thereof | |
| CN112641849A (en) | Pharmaceutical or cosmetic composition for dry skin, and preparation method and application thereof | |
| CN110075178A (en) | A kind of composition for treating corticosteroid dermatitis, preparation and preparation method and application | |
| CN115043804B (en) | Sesquiterpenoids extracted from Dai medicine, dai medicine composition containing sesquiterpenoids and preparation method and application of Dai medicine composition | |
| KR20200109592A (en) | The composition with antioxidant and anti-inflammatory activity containing Lycium chinense leaf extract of Chengyang | |
| WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
| CN114209632B (en) | Pre-washing hair-fixing essential oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |